Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $183.89 Consensus Price Target from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $183.89.

SRPT has been the subject of a number of recent research reports. William Blair upgraded shares of Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. UBS Group raised their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research note on Tuesday, September 17th. Piper Sandler cut their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating for the company in a research note on Thursday, August 8th. BMO Capital Markets raised their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an "outperform" rating in a research note on Monday, June 24th. Finally, Barclays cut their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating for the company in a research note on Thursday, August 8th.

Sarepta Therapeutics Stock Up 2.3 %

NASDAQ SRPT traded up $2.83 on Friday, reaching $127.08. The company had a trading volume of 1,008,011 shares, compared to its average volume of 1,255,771. The company's fifty day moving average is $129.00 and its 200-day moving average is $132.32. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. The firm has a market capitalization of $12.01 billion, a price-to-earnings ratio of 1,155.27 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same period in the prior year, the business posted ($0.27) EPS. The company's quarterly revenue was up 38.9% on a year-over-year basis. On average, research analysts forecast that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares of the company's stock, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Michael Andrew Chambers purchased 37,038 shares of the firm's stock in a transaction on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Riggs Asset Managment Co. Inc. increased its position in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 75 shares in the last quarter. GAMMA Investing LLC boosted its stake in Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 87 shares during the last quarter. EP Wealth Advisors LLC boosted its stake in Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company's stock valued at $774,000 after acquiring an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company's stock valued at $1,000,000 after acquiring an additional 120 shares during the last quarter. Finally, Innealta Capital LLC purchased a new position in Sarepta Therapeutics in the second quarter valued at about $31,000. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.